Lung Cancer
Small Cell Lung Cancer
Combination Cisplatin, Etoposide and Sunitinib for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/II Study [CALGB 30504]
Principal Investigator:
James Hannigan, M.D.
Adventist La Grange Memorial Hospital
(708) 579-3418
Contact: Lisa Deabel
A Randomized Phase II Study of Cisplatin and Etoposide in Combination with Either Hedgehog Inhibitor GDC-0449 or IGF-IR MOAB IMC-A12 for Patients with Extensive Stage Small Cell Lung Cancer [ECOG 1508]
Principal Investigator:
Elyse Schniederman, MD
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
Other
Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men [SWOG 0424]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Lisa Deabel
Non-Small Cell Lung Cancer
A Phase II Study of Induction Chemotherapy followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer [CALGB 30605]
Principal Investigator:
James Hannigan, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Lisa Deabel
A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Sunitinib(NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer [CALGB 30607]
Principal Investigator:
James Hannigan, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Lisa Deabel
A Randomized, Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC #736511, IND #74019) or Pemetrexed plus Sunitinib in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer [CALGB 30704]
Principal Investigator:
James Hannigan, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Lisa Deabel
A Randomized Phase III Double-Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer [CALGB 30801]
Principal Investigator:
James Hannigan, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Lisa Deabel
A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely-Resected Stage 1B) (>4cm) to IIIA Non-Small Cell Lung Cancer (NSCLC) [ECOG 1505]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
AIII Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely-Resected Sta Phase ge 1B) (>4cm) to IIIA Non-Small Cell Lung Cancer (NSCLC) [ECOG 1505]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Lisa Deabel
A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab with or without IMC-A12 in Patients with Advanced Non-Squamous, Non-Small Cell Lung Cancer [ECOG 3805]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
A Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-Small Cell Lung Cancer Patients who will not Receive Bevacizumab-Based Therapy [ECOG 4508]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men [SWOG 0424]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Lisa Deabel
A Randomized, Phase II Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) [SWOG 0819]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Lisa Deabel